Literature DB >> 6180762

Bifunctional intercalation of antitumor antibiotics BBM-928A and echinomycin with deoxyribonucleic acid. Effects of intercalation on deoxyribonucleic acid degradative activity of bleomycin and phleomycin.

C H Huang, A W Prestayko, S T Crooke.   

Abstract

The binding of peptide antitumor antibiotics, BBM-928A and echinomycin, to superhelical PM2 DNA and the effects of the resulting conformational changes of DNA on the DNA-degradative activity of two related antitumor antibiotics, bleomycin A2 and phleomycin D1, have been studied. The bifunctional intercalative mode of the DNA binding of BBM-928A concluded previously from viscometric and fluorometric studies has been confirmed by gel electrophoretic analysis. Under the employed electrophoretic conditions, DNA-bound BBM-928A showed little dissociation whereas echinomycin and ethidium bromide showed partial and nearly complete dissociation, respectively. BBM-928A induced neither single-strand nor double-strand breaks in DNA. Competitive binding studies by fluorescence changes suggested that binding sites on DNA molecules for BBM-928A (or echinomycin) may differ from those for ethidium bromide, since binding to DNA by the two drugs was not competitive even at saturating concentrations. The lack of such a competition between the two drugs is not consistent with the neighbor-exclusion principle. The DNA-degradative activity of both bleomycin A2 and phleomycin D1 increased with the removal of the negative superhelicity of DNA by the BBM-928A intercalation and decreased with the formation of positive superhelical turns induced by high concentrations of BBM-928A. Thus the degradative activity of both bleomycin A2 and phleomycin D1 is sensitive in a similar manner to the degree of superhelicity rather than the double helicity of DNA, although there are differences between these two drugs in interaction with DNA.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6180762     DOI: 10.1021/bi00258a028

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Phase II trial of echinomycin in advanced colorectal cancer. A Southwest Oncology Group study.

Authors:  T D Brown; P J Goodman; T R Fleming; S A Taylor; J S Macdonald
Journal:  Invest New Drugs       Date:  1991-02       Impact factor: 3.850

2.  Sequence-specific binding of luzopeptin to DNA.

Authors:  K R Fox; H Davies; G R Adams; J Portugal; M J Waring
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

3.  Altered cleavage of DNA sequences by bleomycin and its deglycosylated derivative in the presence of actinomycin.

Authors:  C Bailly; A Kénani; M J Waring
Journal:  Nucleic Acids Res       Date:  1997-04-15       Impact factor: 16.971

4.  Echinomycin inhibits chromosomal DNA replication and embryonic development in vertebrates.

Authors:  Laurence G May; Mark A Madine; Michael J Waring
Journal:  Nucleic Acids Res       Date:  2004-01-02       Impact factor: 16.971

5.  Korkormicins, novel depsipeptide antitumor antibiotics from Micromonospora sp C39500: fermentation, precursor directed biosynthesis and biological activities.

Authors:  K S Lam; D R Gustavson; G A Hesler; T T Dabrah; J A Matson; R L Berry; W C Rose; S Forenza
Journal:  J Ind Microbiol       Date:  1995-07

6.  1H- and 13C-n.m.r. studies of the antitumour antibiotic luzopeptin. Resonance assignments, conformation and flexibility in solution.

Authors:  M S Searle; J G Hall; P G Wakelin
Journal:  Biochem J       Date:  1988-11-15       Impact factor: 3.857

7.  In vitro characterization of echinomycin biosynthesis: formation and hydroxylation of L-tryptophanyl-S-enzyme and oxidation of (2S,3S) β-hydroxytryptophan.

Authors:  Chen Zhang; Lingxin Kong; Qian Liu; Xuan Lei; Tao Zhu; Jun Yin; Birun Lin; Zixin Deng; Delin You
Journal:  PLoS One       Date:  2013-02-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.